Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease

References

• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Tarantino G, Crocetto F, Di Vito C, et al. Association of NAFLD and insulin resistance with non metastatic bladder cancer patients: a Cross-Sectional Retrospective Study. J Clin Med. 2021;10(2):346. doi:10.3390/jcm10020346
   PubMed Web of Science ®Google Scholar
• Koh W-P, Dan YY, Goh G-B-B, Jin A, Wang R, Yuan J-M. Dietary fatty acids and risk of hepatocellular carcinoma in the Singapore Chinese health study. Liver Int. 2016;36(6):893–901. doi:10.1111/liv.12978
   PubMed Web of Science ®Google Scholar
• Guidelines ECP. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Chan SL, Wong VWS, Qin S, Chan HLY. Infection and cancer: the case of hepatitis B. J Clin Oncol. 2016;34(1):83–90. doi:10.1200/JCO.2015.61.5724
   PubMed Web of Science ®Google Scholar
• Vallet-Pichard A, Pol S. Review article: immunisation against hepatitis B virus infection and the prevention of hepatocellular carcinoma. Aliment Pharmacol Ther. 2021;53(11):1166–1182. doi:10.1111/apt.16356
   PubMed Web of Science ®Google Scholar
• Brunt EM, Wong VWS, Nobili V, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1:15080. doi:10.1038/nrdp.2015.80
   PubMed Web of Science ®Google Scholar
• Janicko M, Senajová G, Drazilová S, et al. Association between metabolic syndrome and hepatitis B virus infection in the Roma population in eastern Slovakia: a population-based study. Cent Eur J Public Health. 2014;22(Suppl):S37–S42. doi:10.21101/cejph.a3900
   PubMedGoogle Scholar
• Jiang D, Chen C, Liu X, et al. Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta-analysis. Ann Transl Med. 2021;9(23):1718. doi:10.21037/atm-21-3052
   PubMed Web of Science ®Google Scholar
• Zheng KI, Zheng M-H. Letter: hepatitis B and MAFLD - a consilience of risk factors for hepatocellular carcinoma. Aliment Pharmacol Ther. 2021;54(5):736–737. doi:10.1111/apt.16532
   PubMed Web of Science ®Google Scholar
• Chen C-L, Yang H-I, Yang W-S, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135(1):111–121. doi:10.1053/j.gastro.2008.03.073
   PubMed Web of Science ®Google Scholar
• Pickhardt PJ, Graffy PM, Reeder SB, Hernando D, Li K. Quantification of liver fat content with unenhanced MDCT: phantom and clinical correlation with MRI proton density fat fraction. AJR Am J Roentgenol. 2018;211(3):W151–W157. doi:10.2214/AJR.17.19391
   PubMed Web of Science ®Google Scholar
• Hayashi T, Saitoh S, Takahashi J, et al. Hepatic fat quantification using the two-point Dixon method and fat color maps based on non-alcoholic fatty liver disease activity score. Hepatol Res. 2017;47(5):455–464. doi:10.1111/hepr.12767
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Xie D-Y, Ren Z-G, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452–463. doi:10.21037/hbsn-20-480
   PubMed Web of Science ®Google Scholar
• Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–649.
   PubMed Web of Science ®Google Scholar
• Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161(6):1887–1895.e4. doi:10.1053/j.gastro.2021.08.050
   PubMed Web of Science ®Google Scholar
• Conci S, Cipriani F, Donadon M, et al. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: propensity case-matched analysis with viral- and alcohol-related HCC. Eur J Surg Oncol. 2022;48(1):103–112. doi:10.1016/j.ejso.2021.07.015
   PubMed Web of Science ®Google Scholar
• Vitale A, Svegliati-Baroni G, Ortolani A, et al. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database. Gut. 2023;72(1):141–152. doi:10.1136/gutjnl-2021-324915
   PubMed Web of Science ®Google Scholar
• Nan Y, An J, Bao J, et al. The Chinese society of hepatology position statement on the redefinition of fatty liver disease. J Hepatol. 2021;75(2):454–461. doi:10.1016/j.jhep.2021.05.003
   PubMed Web of Science ®Google Scholar
• Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1. doi:10.1053/j.gastro.2019.11.312
   PubMed Web of Science ®Google Scholar
• Hassan MM, Abdel-Wahab R, Kaseb A, et al. Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma. Gastroenterology. 2015;149(1):119–129. doi:10.1053/j.gastro.2015.03.044
   PubMed Web of Science ®Google Scholar
• Di Angelantonio E, Bhupathiraju SN, Wormser D, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388(10046):776–786. doi:10.1016/S0140-6736(16)30175-1
   PubMed Web of Science ®Google Scholar
• Hagström H, Nasr P, Ekstedt M, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study. Hepatol Commun. 2018;2(1):48–57. doi:10.1002/hep4.1124
   PubMed Web of Science ®Google Scholar
• Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020;17(5):279–297. doi:10.1038/s41575-020-0269-9
   PubMed Web of Science ®Google Scholar
• Jarvis H, Craig D, Barker R, et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020;17(4):e1003100. doi:10.1371/journal.pmed.1003100
   PubMed Web of Science ®Google Scholar
• Jensen T, Abdelmalek MF, Sullivan S, et al. Fructose and sugar: a major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018;68(5):1063–1075. doi:10.1016/j.jhep.2018.01.019
   PubMed Web of Science ®Google Scholar
• Nobili V, Mantovani A, Cianfarani S, et al. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. J Hepatol. 2019;71(4):802–810. doi:10.1016/j.jhep.2019.06.023
   PubMed Web of Science ®Google Scholar
• Seto W-K, Hui RWH, Mak L-Y, et al. Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B. Clin Gastroenterol Hepatol. 2018;16(4):575–583.e2. doi:10.1016/j.cgh.2017.09.044
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi:10.1016/j.jhep.2019.06.021
   PubMed Web of Science ®Google Scholar
• Alkhouri N, Dixon LJ, Feldstein AE. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol. 2009;3(4):445–451. doi:10.1586/egh.09.32
   PubMedGoogle Scholar
• Pickhardt PJ, Hahn L, Muñoz Del Rio A, Park SH, Reeder SB, Said A. Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications. AJR Am J Roentgenol. 2014;202(4):752–758. doi:10.2214/AJR.13.11367
   PubMed Web of Science ®Google Scholar
• Graffy PM, Pickhardt PJ. Quantification of hepatic and visceral fat by CT and MR imaging: relevance to the obesity epidemic, metabolic syndrome and NAFLD. Br J Radiol. 2016;89(1062):20151024. doi:10.1259/bjr.20151024
   PubMed Web of Science ®Google Scholar
• Hahn L, Reeder SB, Muñoz Del Rio A, Pickhardt PJ. Longitudinal changes in liver fat content in asymptomatic adults: hepatic attenuation on unenhanced CT as an imaging biomarker for steatosis. AJR Am J Roentgenol. 2015;205(6):1167–1172. doi:10.2214/AJR.15.14724
   PubMed Web of Science ®Google Scholar
• Sartoris R, Gregory J, Dioguardi Burgio M, Ronot M, Vilgrain V. HCC advances in diagnosis and prognosis: digital and imaging. Liver Int. 2021;Suppl 41(S1):73–77. doi:10.1111/liv.14865
   Google Scholar
• Chan AWH, Wong GLH, Chan H-Y, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol. 2017;32(3):667–676. doi:10.1111/jgh.13536
   PubMed Web of Science ®Google Scholar
• Suliman I, Abdelgelil N, Kassamali F, Hassanein TI. The effects of hepatic steatosis on the natural history of HBV infection. Clin Liver Dis. 2019;23(3):433–450. doi:10.1016/j.cld.2019.05.001
   PubMed Web of Science ®Google Scholar
• Mak L-Y, Hui RW-H, Fung J, et al. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. Hepatol Int. 2021;15(4):901–911. doi:10.1007/s12072-021-10218-2
   PubMed Web of Science ®Google Scholar
• Yuen M-F, Chen D-S, Dusheiko GM, et al. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035. doi:10.1038/nrdp.2018.35
   PubMed Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Sun H-C, Zhang W, Qin L-X, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol. 2007;47(5):684–690. doi:10.1016/j.jhep.2007.06.019
   PubMed Web of Science ®Google Scholar
• Liu J, Yang H-I, Lee M-H, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut. 2014;63(10):1648–1657. doi:10.1136/gutjnl-2013-305785
   PubMed Web of Science ®Google Scholar
• Mak L-Y, Hui RW-H, Fung J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73(4):800–806. doi:10.1016/j.jhep.2020.05.040
   PubMed Web of Science ®Google Scholar
• Wong YJ, Nguyen VH, Yang H-I, et al. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis. Clin Mol Hepatol. 2023;29(3):705–720. doi:10.3350/cmh.2023.0004
   PubMed Web of Science ®Google Scholar
• Chen X, Zhou J, Wu L, Zhu X, Deng H. MAFLD is associated with the risk of liver fibrosis and inflammatory activity in HBeAg-negative CHB patients. Diabetes Metab Syndr Obes. 2022;15:673–683. doi:10.2147/DMSO.S351492
   PubMed Web of Science ®Google Scholar
• Goh MJ, Sinn DH, Kim S, et al. Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B. Hepatology. 2020;71(6):2023–2032. doi:10.1002/hep.30973
   PubMed Web of Science ®Google Scholar